<DOC>
	<DOCNO>NCT02341729</DOCNO>
	<brief_summary>The first aim study prove start therapy crush tablet , platelet inhibition expect start therapy intact tablet . Gurbel et al . show 100 % patient ticagrelor treatment decrease baseline platelet aggregation &gt; 10 % 4 hour last maintenance dose . So investigator expect 3 day treatment , patient close time 106seconds . The investigator observe two different clinical condition Acute Coronary Syndrome . First semi-urgent coronary artery bypass graft ( CABG ) surgery , secondly patient cardiac arrest . Both clinical situation crush tablet need give . The second objective determine plasma concentration Ticagrelor AR-C124910XX ( active metabolite ticagrelor ) two patient population receive 180mg 90mg start-dose . Determination plasma concentration do protein precipitation , use liquid chromatography mass spectrometry detection . Measurements determine intake ( 0h ) 0,5 ; 1 ; 2 ; 4 ; 8 ; 24h day 4 +4h.7 The first 24h crushed tablet 4 hour first intake day 4 therapy , non crushed tablet .</brief_summary>
	<brief_title>Effects Plasma Concentration Ticagrelor , After Crushed Non-crushed Intake , After Acute Coronary Syndrome</brief_title>
	<detailed_description>This study single-centre , open-label , non-randomised longitudinal study effect ticagrelor , crush non-crushed evaluated two separate clinical condition . The plasma concentration crush intake use determine maximum plasma concentration time achieve maximum concentration . 50 patient condition : Condition A : patient receive CPR cardiac arrest . A gastric tube insert . Subjects receive 2 crushed tablet ticagrelor ( 180mg ) 10 ml water flush 20 ml water . The first blood sample take administration . The following sample take 30minutes , 1 , 2 , 4 , 8 , 12 , 24h . The ninth sample take 24 hour stop sedation 4h administration ticagrelor 10 ml water flush 20 ml water via nasogastric tube . The tenth sample take 4 day 4hours first intake ticagrelor , last sample mostly non-crushed intake ticagrelor ( depend neurological condition patient ) . Only first dose load dose 180mg , hereafter normal dose 90mg give . At blood sample moment 1 2 sample take ( see also flow chart ) . At time 0 , 2 , 4 , 8 , 12 , 24h , 24h sedation stop 4 day 4hours first intake ticagrelor : Platelet Function Analysis Aggreguide aggregometry do . For analysis 3,6ml blood need , make total 28,8ml clotting analysis . At time 30min , 1 , 2 , 4 , 8 , 24h 4 day 4h ; 4ml blood need plasma concentration measurement , total 28ml . Condition B : Patients need semi-urgent coronary bypass surgery , allow interrupt administration ticagrelor 3 day surgery . A nasogastric tube insert surgery . On intensive care patient receive crush tablet ticagrelor 10 ml water flush 20 ml water via gastric tube , first dose load dose . The first blood sample take surgery ( weak effect ticagrelor administration stop 3 day ) . The following sample take 30minutes , 1 , 2 , 4 , 8 , 12 , 24h . The ninth sample take 24 hour stop sedation 4h administration ticagrelor 10 ml water flush 20 ml water via nasogastric tube . The tenth sample take 4 day 4hours first intake ticagrelor , last sample mostly non-crushed intake ticagrelor ( depend neurological condition patient ) . Only first dose load dose 180mg , hereafter normal dose 90mg give . At blood sample moment 1 2 sample take ( see also flow chart ) . At time 0 , 2 , 4 , 8 , 12 , 24h , 24h sedation stop 4 day 4hours first intake ticagrelor : Platelet Function Analysis Aggreguide aggregometry do . For analysis 3,6ml blood need , make total 25,2ml clotting analysis . At time 30min , 1 , 2 , 4 , 8 , 24h 4 day 4h ; 4ml blood need plasma concentration measurement , total 28ml .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Subject acute myocardial infarction ST elevation Subject acute myocardial infarction without ST elevation Subject unstable angina ( progressive angina past 2 week , negative cardiac marker , Trop T &lt; 0,014μg/l First time take Brilique ≥ 18 year Possibility take blood sample administration Brilique Signed Informed Consent , sign subject authorized representative , able willing provide write informed consent study participation Active haemorrhage Moderate severe liver failure coagulopathy Pregnancy lactation A history intra cerebral haemorrhage Patient HIV positive treat Ritonavir /or Atazanavir Patient treat vitamin K antagonist new oral anti coagulant Hypersensitivity ticagrelor excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>semi-urgent CABG</keyword>
	<keyword>reanimation</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>crush tablet</keyword>
</DOC>